Nyxoah’s Cash Runway Nears Breaking Point as U.S. Launch Drives Explosive Growth and Relentless Burn

The thesis that the U.S. launch is live and driving explosive growth has been validated by the numbers. For the first time, the company reported a full quarter of sales following the August FDA approval, and the results confirm a successful commercial catalyst. The precise U.S. revenue figure for Q4 2025 was $4.5 million, representing the initial sales from the commercial launch period. This marks a clear inflection point, with the full-year 2025 net revenue total reaching €10.0 million, reflecting a staggering 122% year-over-year growth.

The launch foundation is being built with precision. Management has trained 145 surgeons across 125 high-volume accounts and secured 57 value analysis committee approvals out of 120 submissions by year-end. This structured rollout, focused on high-volume centers, is a disciplined approach to driving adoption. The reimbursement setup is also stable, with Medicare representing 10% and commercial payers 90% of the U.S. business, providing clarity for new hospital accounts.

Yet the path to profitability remains steep. While the top-line acceleration is impressive, it is being funded by massive investment. The full-year 2025 operating loss ballooned to €83.5 million, up from €58.8 million the prior year, directly tied to U.S. commercialization activities. This burn is a binary risk, with the cash position of €48 million supporting operations at a rate of approximately €20 million per quarter into 2027. The catalyst is confirmed, but the financial runway is tight, making the next phase of execution critical.

Financial Mechanics: The Cost of the Ramp and Cash Runway

The numbers confirm a steep price for the commercial ramp. While the top-line growth is explosive, the bottom-line impact is severe. For the fourth quarter, the company reported a gross margin of approximately 64%, a solid starting point. Yet this was overshadowed by a basic EPS loss of €0.586 for the quarter and a trailing twelve-month loss of €2.364 per share. The core issue is that operating losses are ballooning faster than revenue.

The full-year 2025 operating loss reached €83.5 million, a significant increase from €58.8 million in 2024. This widening gap is the direct cost of building the U.S. launch infrastructure. The company is spending heavily to train surgeons, secure hospital accounts, and drive adoption, all of which is being booked as an expense. This burn is now a clear binary risk to the stock.

The cash position at year-end was €48.0 million. With operating losses running at roughly €20 million to €24 million per quarter, this provides a runway of about 2 to 2.5 quarters. That places the company's financial runway into the first half of 2027. This is not a long-term funding plan; it is a short-term burn rate that demands the next phase of growth to accelerate quickly to avoid a dilutive capital raise. The catalyst is confirmed, but the financial mechanics show a company operating at a massive deficit, with its cash position a direct function of how fast it can scale revenue to offset this relentless burn.

Next Catalysts and Immediate Risk/Reward Setup

The immediate setup is defined by a series of binary events that will test the growth thesis against the company's financial runway. The primary near-term catalyst is the planned expansion of the U.S. sales force to 40 sales representatives covering 200 accounts in 2026. This is a direct execution step from the current 25 reps and 125 accounts. Success here is non-negotiable; it must translate into a measurable acceleration of the implant rate to justify the burn and extend the cash runway.

Beyond this operational ramp, several key catalysts are on the horizon. The timeline for securing value analysis committee (VAC) approvals remains a critical variable. Management reported 57 approvals and 63 pending submissions by year-end, but the process is hospital-specific and can vary significantly. Each approval unlocks a new account, so the pace of conversion from pending to approved will directly impact near-term revenue visibility.

More substantive data catalysts are also scheduled. The company expects to report ACCESS study data by July 2026, which will provide additional clinical evidence to support the product's efficacy. Simultaneously, the submission of a PMA supplement for label expansion is in the pipeline, aiming to broaden the patient population eligible for treatment. These events could provide a meaningful tailwind to the commercial narrative later this year.

The stock's current valuation reflects this high-stakes setup. With a market capitalization of approximately $116 million, it trades at a steep premium to its current revenue base. The company's full-year 2025 net revenue was just €10.0 million, and the stock has fallen sharply from its peak, shedding over a third of its value in the past month. This discount prices in significant execution risk. The binary bet is clear: if the sales force expansion and VAC approvals drive revenue growth faster than the €20 million quarterly burn, the stock could re-rate. If not, the pressure for a dilutive capital raise intensifies, making the current valuation a trap for those who misjudge the timeline.